| Literature DB >> 34067695 |
Leonardo Anchique1, Jackson J Alcázar2, Andrea Ramos-Hernandez1, Maximiliano Méndez-López3, José R Mora4, Norma Rangel5, José Luis Paz6, Edgar Márquez3.
Abstract
The occurrence, persistence, and accumulation of antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) represent a new environmental problem due to their harmful effects on human and aquatic life. A suitable absorbent for a particular type of pollutant does not necessarily absorb other types of compounds, so knowing the compatibility between a particular pollutant and a potential absorbent before experimentation seems to be fundamental. In this work, the molecular interactions between some pharmaceuticals (amoxicillin, ibuprofen, and tetracycline derivatives) with two potential absorbers, chitosan and graphene oxide models (pyrene, GO-1, and coronene, GO-2), were studied using the ωB97X-D/6-311G(2d,p) level of theory. The energetic interaction order found was amoxicillin/chitosan > amoxicillin/GO-1 > amoxicillin/GO-2 > ibuprofen/chitosan > ibuprofen/GO-2 > ibuprofen/GO-1, the negative sign for the interaction energy in all complex formations confirms good compatibility, while the size of Eint between 24-34 kcal/mol indicates physisorption processes. Moreover, the free energies of complex formation were negative, confirming the spontaneity of the processes. The larger interaction of amoxicillin Gos, compared to ibuprofen Gos, is consistent with previously reported experimental results, demonstrating the exceptional predictability of these methods. The second-order perturbation theory analysis shows that the amoxicillin complexes are mainly driven by hydrogen bonds, while van der Waals interactions with chitosan and hydrophobic interactions with graphene oxides are modelled for the ibuprofen complexes. Energy decomposition analysis (EDA) shows that electrostatic energy is a major contributor to the stabilization energy in all cases. The results obtained in this work promote the use of graphene oxides and chitosan as potential adsorbents for the removal of these emerging pollutants from water.Entities:
Keywords: absorption; density functional theory; emergent pollutants; natural bond orbital; pharmaceuticals
Year: 2021 PMID: 34067695 PMCID: PMC8156938 DOI: 10.3390/polym13101620
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1Left: minimum energy structures at ωB97X-D/6-311G(2d,p) level of theory. (A) amoxicillin; (B) ibuprofen; (C) graphene oxide (pyrene, GO-1); (D) graphene oxide (coronene, GO-2); and (E) chitosan. On the right, electrostatic potential (ESP) surface; scale in kcal/mol.
Figure 2Frontier molecular orbitals for compounds studied in this work. HOMO: Highest occupied molecular orbital; LUMO: lowest unoccupied molecular Orbital obtained at wB97X-D/6311G(2d,p) theory level. AMOX = amoxicillin; IBU = ibuprofen; CS = chitosan; GO-1 = pyrene-based graphene; GO-2 = coronene-based graphene.
Figure 3Optimized structures at ωB97X-D/6-311G(2d.p) level of theory for all complexes studied in this work. (A) amoxicillin-chitosan; (B) ibuprofen-chitosan; (C) amoxicillin-GO-1; (D) amoxicillin-GO-2; (E) ibuprofen-GO-1; (F) ibuprofen-GO-2. The dashed line suggests an important molecular interaction.
Thermodynamic parameters for the complexation of amoxicillin, ibuprofen, tetracycline, oxytetracycline and doxycycline with chitosan and graphene oxides, calculated at 298.15 K and 1 atm, using the ωB97X-D/6-31G++(d,p) theory level.
| Complex | ΔH | ΔS | ΔG | ΔET |
|---|---|---|---|---|
| AMOX-CS | −42.53 | −61.78 | −24.11 | −25.36 |
| AMOX-GO-1 | −36.64 | −59.55 | −18.88 | −21.63 |
| AMOX-GO-2 | −39.65 | −79.53 | −15.93 | −24.71 |
| IBU-CS | −27.84 | −57.45 | −10.71 | −22.85 |
| IBU-GO-1 | −21.06 | −50.55 | −5.99 | −22.30 |
| IBU-GO-2 | −24.51 | −54.68 | −8.21 | −19.41 |
| Tetracycline-CS | −21.06 | −51.31 | −5.76 | −22.73 |
| Oxytetracycline-CS | −37.63 | −65.33 | −18.15 | −31.78 |
| doxycycline-CS | −22.98 | −52.94 | −7.20 | −23.78 |
| Tetracycline-GO-1 | −22.56 | −54.83 | −6.22 | −23.29 |
| Oxytetracycline-GO-1 | −20.26 | −48.71 | −5.74 | −22.95 |
| Doxycycline-GO-1 | −29.10 | −60.42 | −11.09 | −26.70 |
| Tetracycline-GO-2 | −18.56 | −50.83 | −3.41 | −18.09 |
| Oxytetracycline-GO-2 | −16.26 | −44.71 | −2.93 | −18.47 |
| Doxycycline-GO-2 | −27.10 | −56.42 | −10.28 | −26.03 |
Conceptual DFT molecular descriptors * calculated from frontier orbitals, for the complex drugs-absorbent at ωB97X-D/6-31++G(d,p).
| Molecular | AMOX-CS | IBU-CS | AMOX-GO-1 | AMOX-GO-2 | IBU-GO-1 | IBU-GO-2 |
|---|---|---|---|---|---|---|
| HOMO | −188.77 | −196.17 | −159.85 | −155.27 | −161.78 | −156.46 |
| LUMO | 30.21 | 29.21 | −10.09 | −22.89 | −11.05 | −23.65 |
| µ global | −79.28 | −83.48 | −84.97 | −89.08 | −86.41 | −90.05 |
| η global | 109.49 | 112.69 | 74.88 | 66.19 | 75.36 | 66.40 |
| ΔN | −413.36 | −154.32 | −213.62 | −212.89 | −145.44 | −111.66 |
* HOMO, LUMO, µ global and η global in kcal/mol.
The second-order perturbation theory for amoxicillin and ibuprofen with chitosan and graphene-oxides dimers, by using Fock matrix from Natural Bond Orbital (NBO) calculation at the ωB97X-D/6-31G++(d,p) theory level.
| Donator | Acceptor |
| Donator | Acceptor |
|
|---|---|---|---|---|---|
| Amoxcicillin-Chitosan | |||||
| BD C14-H18 | BD* O89-H90 | 0.29 | LP(2)O66 | BD* N33-H34 | 0.29 |
| BD N33-H34 | BD* N67-H68 | 0.56 | LP(2)O66 | BD* O31-H32 | 1.51 |
| LP O29 | BD* C48-H54 | 0.21 | LP(2)O66 | BD* N33-H34 | 0.29 |
| LP O31 | BD* C49-H55 | 0.86 | LP N67 | BD* C4-H8 | 0.23 |
| LP N33 | BD* N67-H68 | 17.25 | LP(1)O88 | BD* C2-H10 | 0.40 |
| LP O36 | BD* O89-H90 | 0.43 | LP(1)O88 | BD* C12-H15 | 0.69 |
| LP O33 | BD* O89-H90 | 25.72 | LP(2)O88 | BD* C12-H15 | 1.28 |
| BD C65-O66 | BD* O31-H32 | 4.54 | LP(1)O91 | BD* C1-H6 | 0.88 |
| BD C71-O91 | BD* C2-H10 | 0.34 | LP(1)O91 | BD* C4-H8 | 0.21 |
| BD C87-O88 | BD* C2-H10 | 0.63 | LP(2)O91 | BD* C4-H8 | 0.77 |
| BD C87-O88 | BD* C12-H15 | 0.23 | BD C8-C9 | BD* C70-C71 | 0.25 |
| BD O89-H90 | BD* C14-O36 | 0.49 | BD C13-C14 | BD* C72-C73 | 0.21 |
| LP(1)O66 | BD* O31-H32 | 4.77 | BD C15-C16 | LP*(1)C84 | 0.62 |
| LP(2)O66 | BD* O31-H32 | 1.51 | LP(1)O67 | BD* N88-H89 | 0.47 |
| Ibuprofen-Chitosan | |||||
| LP O27 | BD* O63-H64 | 1.50 | BD C49 - H55 | BD* C13-H16 | 0.23 |
| LP O27 | BD* O63-H 64 | 23.05 | BD C51 - C52 | BD* C5-H9 | 0.20 |
| LP O41 | BD* C 48-H 54 | 0.20 | BD C53 - C59 | RY* H7 | 0.55 |
| LP O41 | BD* C 48-H 54 | 0.75 | BD C61 - O62 | RY* H18 | 0.26 |
| BD C48-C49 | RY* H16 | 0.27 | BD C61 - O62 | BD* C14-H18 | 0.94 |
| BD C48-C53 | RY* H7 | 0.29 | BD O63 - H64 | BD* C24-O27 | 0.36 |
| BD C 48-C53 | BD* C3-H7 | 0.24 | LP O62 | BD* C14-H18 | 0.35 |
| LP O62 | BD* N43-H45 | 2.20 | LP O62 | BD* N43-H45 | 1.14 |
| Amoxicillin-GO-1 | |||||
| BD C7-C8 | BD* C50-C51 | 0.41 | BD C50-C51 | LP(1)C3 | 0.70 |
| BD C41-O42 | BD* N68-H69 | 1.24 | BD C50-C51 | LP*(1)C4 | 0.78 |
| BD C41-O42 | BD* C72-O77 | 1.11 | BD C64-O76 | BD* O47-H48 | 3.44 |
| BD O47-H48 | BD* C64-O76 | 0.34 | LP(1)O76 | BD* O47-H48 | 13.39 |
| BD O47-H48 | BD* C64-O76 | 0.60 | LP(1)O83 | BD* O43-H44 | 2.56 |
| LP(1)O42 | BD* N68-H69 | 3.63 | LP(2)O83 | BD* O43-H44 | 2.43 |
| LP(2)O42 | BD* N68-H69 | 3.74 | BD* C52-C53 | BD* C13-C14 | 0.26 |
| BD* C7-C8 | BD* C54-C55 | 0.67 | BD* C54-C55 | BD* C13-C14 | 0.53 |
| BD*C41-O42 | BD* N68-H69 | 0.29 | BD* C64-O76 | BD* O47-H48 | 1.60 |
| Amoxicillin-GO-2 | |||||
| BD C8-C9 | BD* C70-C71 | 0.25 | BD* C41-C42 | BD* C74-C75 | 0.55 |
| BD C13-C14 | BD* C72-C73 | 0.21 | BD C61-O62 | LP*(1)H105 | 3.46 |
| BD C15-C16 | LP*(1)C84 | 0.62 | LP(1)O62 | LP*(1)H105 | 2.53 |
| LP(1)O67 | BD* N88-H89 | 0.47 | LP(2)O62 | LP*(1)H105 | 4.90 |
| LP(2)O67 | BD* N88-H89 | 2.32 | BD* C61-O62 | LP*(1)H105 | 3.70 |
| BD* C11-C12 | BD* C70-C71 | 1.85 | BD* C41-C42 | BD* C74-C75 | 0.55 |
| IBU-GO-1 | |||||
| LP(1)O72 | BD* O47-H48 | 6.81 | BD C69-O70 | BD* O47-H48 | 0.22 |
| LP(2)O72 | BD* O47-H48 | 11.48 | BD C69-O72 | BD* C13-H15 | 0.42 |
| BD C22-C23 | BD* C79-H82 | 0.20 | BD C69-O72 | BD* O47-H48 | 0.40 |
| IBU-GO-2 | |||||
| LP(1)O62 | BD* O92-H91 | 8.38 | LP (1)O92 | LP*(1)C61 | 0.32 |
| BD C72-C73 | BD* C10-C27 | 0.22 | LP (2)O92 | LP*(1)C61 | 1.26 |
| BD C89-O92 | BD* C21-C22 | 0.38 | BD* C89-O92 | BD* C1-C6 | 0.26 |
| LP(2)O90 | BD* C21-C22 | 0.31 | BD* C89-O92 | BD* C21-C22 | 0.37 |
* Antibonding; LP: lone-pair; BD: Bonding
Decomposition analysis of total binding energy (ΔET) for the complexes studies herein.
| Complex | ΔEelect | ΔEoi | ΔEPauli | ΔEint | ΔET | ΔEprep |
|---|---|---|---|---|---|---|
| AMOX-CS | −64.44 | −32.31 | 52.37 | −34.70 | −25.36 | 9.41 |
| AMOX-GO-1 | −26.79 | −21.06 | 7.39 | −33.21 | −21.63 | 11.62 |
| AMOX-GO-2 | −24.59 | −21.82 | 7.89 | −31.33 | −24.71 | 6.31 |
| IBU-CS | −30.23 | −19.79 | 17.26 | −25.50 | −22.85 | 2.62 |
| IBU-GO-1 | −13.29 | −11.95 | −3.47 | −24.41 | −22.30 | 2.10 |
| IBU-GO-2 | −22.32 | −12.00 | 7.24 | −23.21 | −19.41 | 3.80 |